Mirati Therapeutics (NASDAQ: MRTX)
Some price data may be temporarily unavailable.
Mirati Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Mirati Therapeutics Company Info
Mirati Therapeutics is at the forefront of precision medicine, with a pipeline full of drugs targeting tumors expressing specific mutations.
News & Analysis
Why Shares of Mirati Therapeutics Are Jumping Wednesday
The company replaced its CEO and reported strong revenue growth.
Why Shares of Mirati Therapeutics Fell Wednesday
The company presented phase 2 data from its non-small cell lung cancer therapy.
Why Shares of Mirati Therapeutics Fell Tuesday
Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.
3 Stocks Expecting Good News From the FDA
Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.
Why Mirati Therapeutics Stock Is Skyrocketing This Week
The company presented great data at the American Society of Clinical Oncology annual meeting.
Why Mirati Therapeutics Stock Is Plunging Today
A longer-than-expected regulatory review for the company's lung cancer drug is weighing on its shares today.
Why Mirati Therapeutics Was Sinking This Week
A rival to the company's leading pipeline drug wins conditional marketing authorization in a big market abroad.
Why Mirati Therapeutics Stock Is Taking Off Today
The biotech's positive clinical results announced on Sunday prompted analysts to boost their price targets on the stock.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.